Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Regulatory News (ONC)

  • This share is currently suspended. It was suspended at a price of 1.2699
  • There is currently no data for ONC

Holding(s) in Company

1 Apr 2021 07:00

RNS Number : 2093U
Oncimmune Holdings PLC
01 April 2021
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Oncimmune Holdings plc

 

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Balderton Capital III, L.P.

City and country of registered office (if applicable)

Delaware, United States

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

30 March 2021

6. Date on which issuer notified (DD/MM/YYYY):

31 March 2021

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

9.9%

N/A

9.9%

69,097,540

Position of previous notification (if

applicable)

13.35%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

6,813,196

N/A

9.9%

N/A

SUBTOTAL 8. A

6,813,196

9.9%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

x

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

London, UK

Date of completion

31.03.21

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUAOBRAVUOOAR
Date   Source Headline
28th Apr 20257:00 amRNSCancellation - ONCIMMUNE HOLDINGS PLC
26th Mar 202512:45 pmRNSAppointment of Administrators & Nomad Resignation
19th Mar 20257:00 amRNSHolding(s) in Company
17th Mar 20257:30 amRNSSuspension - Oncimmune Holdings Plc
17th Mar 20257:00 amRNSIntention to Appoint Administrators and Suspension
14th Mar 20257:00 amRNSBlock Listing Return
10th Mar 20251:39 pmRNSResult of GM
27th Feb 20254:18 pmRNSResult of AGM
24th Feb 20257:00 amRNSStrategic update
18th Feb 20257:00 amRNSHolding(s) in Company
12th Feb 20257:01 amRNSBlock Listing Return
12th Feb 20257:00 amRNSPosting of Notice of General Meeting
10th Feb 20257:00 amRNSFinal Results
4th Feb 202510:38 amRNSHolding(s) in Company
3rd Feb 20257:00 amRNSNotice of Annual General Meeting
31st Jan 20257:00 amRNSTrading Update
10th Dec 20243:36 pmRNSHolding(s) in Company
4th Dec 20241:38 pmRNSHolding(s) in Company
13th Nov 20245:06 pmRNSHolding(s) in Company
13th Nov 202411:41 amRNSHolding(s) in Company
12th Nov 20245:17 pmRNSHolding(s) in Company
12th Nov 20244:49 pmRNSHolding(s) in Company
11th Nov 202411:15 amRNSDirector/PDMR Shareholding
8th Nov 20242:37 pmRNSResults of General Meeting and Total Voting Rights
31st Oct 20245:07 pmRNSResult of Retail Offer
31st Oct 20247:00 amRNSTrading Update
23rd Oct 20244:12 pmRNSPosting of Circular and Notice of General Meeting
18th Oct 20243:05 pmRNSResult of Placing & Issue of Equity
18th Oct 20248:00 amRNSRetail Offer
18th Oct 20247:47 amRNSFundraising and Amendments to Facility
9th Sep 20247:00 amRNSTrading Update
2nd Sep 20247:00 amRNSContract Win
9th Aug 20247:00 amRNSUS$1.5m Contract Win with Top 10 Pharma Company
24th Jun 202411:18 amRNSHolding(s) in Company
17th Jun 20242:30 pmRNSHolding(s) in Company
29th May 20245:45 pmRNSHolding(s) in Company
21st May 20247:00 amRNSInterim Results
17th May 202410:11 amRNSInvestor Presentation via Investor Meet Company
9th May 20243:08 pmRNSHolding(s) in Company
26th Apr 20247:00 amRNSAppointment of Nominated Adviser and Joint Broker
25th Apr 202410:44 amRNSHolding(s) in Company
2nd Apr 202411:34 amRNSResult of General Meeting
2nd Apr 20248:00 amRNSTotal Voting Rights
26th Mar 202411:18 amRNSHolding(s) in Company
13th Mar 20245:32 pmRNSBlock Listing Return
6th Mar 20243:02 pmRNSPosting of Notice of General Meeting
1st Mar 20241:00 pmRNSInvestor Presentation via Investor Meet Company
29th Feb 202411:19 amRNSHolding(s) in Company
29th Feb 20247:00 amRNSFinal Results
26th Feb 202411:30 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.